MicroRNA let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt lymphoma cells

Cancer Research

Volumn 67, Issue 20, 2007, Pages 9762-9770

  Sampson, Valerie B ^a   Rong, Nancy H ^a   Han, Jian ^b   Yang, Qunying ^b   Aris, Virginie ^c   Soteropoulos, Patricia ^c   Petrelli, Nicholas J ^d   Dunn, Stephen P ^a   Krueger, Leslie J ^a,e  

^a NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

^b QIAGEN North America   (United States)

^c PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

^d HELEN F GRAHAM CANCER CENTER   (United States)

^e NEMOURS CHILDREN S CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; MICRORNA; MYC PROTEIN;

ANIMAL CELL; ARTICLE; BURKITT LYMPHOMA; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENETIC TRANSFECTION; LET 7A GENE; LET 7B GENE; MIR 98 GENE; NONHUMAN; ONCOGENE; ONCOGENE MYC; PHENOTYPE; PRIORITY JOURNAL; RAT; TUMOR GROWTH;

ANIMALS; BASIC-LEUCINE ZIPPER TRANSCRIPTION FACTORS; BURKITT LYMPHOMA; CELL GROWTH PROCESSES; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENES, MYC; HUMANS; MICRORNAS; PROTO-ONCOGENE PROTEINS C-MYC; RATS; RNA, MESSENGER; RNA, SMALL INTERFERING;

EID: 35449003175     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-2462     Document Type: Article

References (50)

1. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998;391:806-11.
2. Baehrecke EH. miRNAs:micro managers of programmed cell death. Curr Biol 2003;13:R473-5.
3. He L, Thomson JM, Hemann MT, et al. A microRNA polycistron as a potential human oncogene. Nature 2005;435:828-33.
4. Pfeffer S, Zavolan M, Grasser FA, et al. Identification of virus-encoded microRNAs. Science 2004;304:734-6.
5. Chen CZ, Li L, Lodish HF, Bartel DP. MicroRNAs modulate hematopoietic lineage differentiation. Science 2004;303:83-6.
6. Lee Y, Jeon K, Lee JT, Kim S, Kim VN. MicroRNA maturation: stepwise processing and subcellular localization. EMBO J 2002;21:4663-70.
7. Han J, Lee Y, Yeom KH, Kim YK, Jin H, Kim VN. The Drosha-DGCR8 complex in primary microRNA processing. Genes Dev 2004;18:3016-27.
8. Hutvagner G, Zamore PD. A microRNA in a multiple-turnover RNAi enzyme complex. Science 2002;297: 2056-60.
9. Luscher B, Eisenman RN. New light on Myc and Myb. Part II. Myb. Genes Dev 1990;4:2235-41.
10. Persson H, Hennighausen L, Taub R, DeGrado W, Leder P. Antibodies to human c-myc oncogene product: evidence of an evolutionarily conserved protein induced during cell proliferation. Science 1984;225:687-93.
11. Eilers M, Schirm S, Bishop JM. The MYC protein activates transcription of the α-prothymosin gene. EMBO J 1991;10:133-41.
12. Vennstrom B, Sheiness D, Zabielski J, Bishop JM. Isolation and characterization of c-myc, a cellular homolog of the oncogene (v-myc) of avian myelocytomatosis virus strain 29. J Virol 1982;42:773-9.
13. Facchini LM, Penn LZ. The molecular role of Myc in growth and transformation: recent discoveries lead to new insights. FASEB J 1998;12:633-51.
14. Amati B, Littlewood TD, Evan GI, Land H. The c-Myc protein induces cell cycle progression and apoptosis through dimerization with Max. EMBO J 1993;12:5083-7.
15. Grinberg AV, Hu CD, Kerppola TK. Visualization of Myc/Max/Mad family dimers and the competition for dimerization in living cells. Mol Cell Biol 2004;24: 4294-308.
16. Pelengaris S, Khan M, Evan GI. Suppression of Myc-induced apoptosis in β cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell 2002;109:321-34.
17. Osthus RC, Shim H, Kim S, et al. Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. J Biol Chem 2000;275:21797-800.
18. Cole MD, McMahon SB. The Myc oncoprotein: a critical evaluation of transactivation and target gene regulation. Oncogene 1999;18:2916-24.
19. McManus MT. MicroRNAs and cancer. Semin Cancer Biol 2003;13:253-8.
20. Yin X, Giap C, Lazo JS, Prochownik EV. Low molecular weight inhibitors of Myc-Max interaction and function. Oncogene 2003;22:6151-9.
21. Mateyak MK, Obaya AJ, Adachi S, Sedivy JM. Phenotypes of c-Myc-deficient rat fibroblasts isolated by targeted homologous recombination. Cell Growth Differ 1997;8:1039-48.
22. Gomez-Curet I, Perkins RS, Bennett R, Feidler KL, Dunn SP, Krueger LJ. c-Myc inhibition negatively impacts lymphoma growth. J Pediatr Surg 2006;41:207-11.
23. Lawrence JB, Villnave CA, Singer RH. Sensitive, high-resolution chromatin and chromosome mapping in situ: presence and orientation of two closely integrated copies of EBV in a lymphoma line. Cell 1988;52:51-61.
24. Hann SR, Eisenman RN. Proteins encoded by the human c-myc oncogene: differential expression in neoplastic cells. Mol Cell Biol 1984;4:2486-97.
25. Basso K, Margolin AA, Stolovitzky G, Klein U, la-Favera R, Califano A. Reverse engineering of regulatory networks in human B cells. Nat Genet 2005;37:382-90.
26. Fernandez PC, Frank SR, Wang L, et al. Genomic targets of the human c-Myc protein. Genes Dev 2003;17: 1115-29.
27. O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT. c-Myc-regulated microRNAs modulate E2F1 expression. Nature 2005;435:839-43.
28. Johnson SM, Grosshans H, Shingara J, et al. RAS is regulated by the let-7 microRNA family. Cell 2005;120: 635-47.
29. Akao Y, Nakagawa Y, Naoe T. let-7 microRNA functions as a potential growth suppressor in human colon cancer cells. Biol Pharm Bull 2006;29:903-6.
30. Johnston RJ, Jr., Chang S, Etchberger JF, Ortiz CO, Hobert O. MicroRNAs acting in a double-negative feedback loop to control a neuronal cell fate decision. Proc Natl Acad Sci U S A 2005;102:12449-54.
31. Hossain A, Kuo MT, Saunders GF. Mir-17-5p regulates breast cancer cell proliferation by inhibiting translation of AIB1 mRNA. Mol Cell Biol 2006;26:8191-201.
32. Sylvestre Y, De Guire V, Querido E, et al. An E2F/miR-20a autoregulatory feedback loop. J Biol Chem 2007;282: 2135-43.
33. Woods K, Thomson JM, Hammond SM. Direct regulation of an oncogenic micro-RNA cluster by E2F transcription factors. J Biol Chem 2007;282:2130-4.
34. Pillai RS, Artus CG, Filipowicz W. Tethering of human Ago proteins to mRNA mimics the miRNA-mediated repression of protein synthesis. RNA 2004;10:1518-25.
35. Valencia-Sanchez MA, Liu J, Hannon GJ, Parker R. Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev 2006;20:515-24.
36. Llave C, Xie Z, Kasschau KD, Carrington JC. Cleavage of Scarecrow-like mRNA targets directed by a class of Arabidopsis miRNA. Science 2002;297:2053-6.
37. Bagga S, Bracht J, Hunter S, et al. Regulation by let-7 and lin-4 miRNAs results in target mRNA degradation. Cell 2005;122:553-63.
38. Didiano D, Hobert O. Perfect seed pairing is not a generally reliable predictor for miRNA-target interactions. Nat Struct Mol Biol 2006;13:849-51.
39. Maroney PA, Yu Y, Fisher J, Nilsen TW. Evidence that microRNAs are associated with translating messenger RNAs in human cells. Nat Struct Mol Biol 2006;13:1102-7.
40. Kim J, Krichevsky A, Grad Y, et al. Identification ofmany microRNAs that copurify with polyribosomes in mammalian neurons. Proc Natl Acad Sci U S A 2004;101:360-5.
41. Arvanitis C, Felsher DW. Conditional transgenic models define how MYC initiates and maintains tumorigenesis. Semin Cancer Biol 2006;16:313-7.
42. Shachaf CM, Felsher DW. Tumor dormancy and MYC inactivation: pushing cancer to the brink of normalcy. Cancer Res 2005;65:4471-4.
43. Marinkovic D, Marinkovic T, Mahr B, Hess J, Wirth T. Reversible lymphomagenesis in conditionally c-MYC expressing mice. Int J Cancer 2004;110:336-42.
44. Pelengaris S, Khan M, Evan G. c-MYC: more than just a matter of life and death. Nat Rev Cancer 2002;2:764-76.
45. Jain M, Arvanitis C, Chu K, et al. Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science 2002;297:102-4.
46. Pelengaris S, Abouna S, Cheung L, Ifandi V, Zervou S, Khan M. Brief inactivation of c-Myc is not sufficient for sustained regression of c-Myc-induced tumours of pancreatic islets and skin epidermis. BMC Biol 2004;2:26.
47. Boxer RB, Jang JW, Sintasath L, Chodosh LA. Lack of sustained regression of c-MYC-induced mammary adenocarcinomas following brief or prolonged MYC inactivation. Cancer Cell 2004;6:577-86.
48. Karlsson A, Giuriato S, Tang F, Fung-Weier J, Levan G, Felsher DW. Genomically complex lymphomas undergo sustained tumor regression upon MYC inactivation unless they acquire novel chromosomal translocations. Blood 2003;101:2797-803.
49. Smythe WR, Mohuiddin I, Ozveran M, Cao XX. Antisense therapy for malignant mesothelioma with oligonucleotides targeting the bcl-xl gene product. J Thorac Cardiovasc Surg 2002;123:1191-8.
50. Giuriato S, Ryeom S, Fan AC, et al. Sustained regression of tumors on MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch2. Proc Natl Acad Sci U S A 2006;103:16266-71.